Two-protein signature of novel serological markers apolipoprotein-A2 and serum amyloid alpha predicts prognosis in patients with metastatic renal cell cancer and improves the currently used prognostic survival models
Background: In metastatic renal cell cancer (mRCC), the Memorial Sloan-Kettering Cancer Center (MSKCC) risk model is widely used for clinical trial design and patient management. To improve prognostication, we applied proteomics to identify novel serological proteins associated with overall survival (OS). Patients and methods: Sera from 114 mRCC patients were screened by surface-enhanced laser desorption ionization time-of-flight mass spectrometry (SELDI-TOF MS). Identified proteins were related to OS. Three proteins were subsequently validated with enzyme-linked immunosorbent assays and immunoturbidimetry. Prognostic models were statistically bootstrapped to correct for overestimation. Results: SELDI-TOF MS detected 10 proteins associated with OS. Of these, apolipoprotein A2 (ApoA2), serum amyloid alpha (SAA) and transthyretin were validated for their association with OS (P = 5.5×10-9, P = 1.1×0-7 and P = 0.0004, respectively). Combining ApoA2 and SAA yielded a prognostic two-protein signature [Akaike's Information Criteria (AIC) = 732, P = 5.2×10-7]. Including previously identified prognostic factors, multivariable Cox regression analysis revealed ApoA2, SAA, lactate dehydrogenase, performance status and number of metastasis sites as independent factors for survival. Using these five factors, categorization of patients into three risk groups generated a novel protein-based model predicting patient prognosis (AIC = 713, P = 4.3×10-11) more robustly than the MSKCC model (AIC = 729, P = 1.3×10-7). Applying this protein-based model instead of the MSKCC model would have changed the risk group in 38% of the patients. Conclusions: Proteomics and subsequent validation yielded two novel prognostic markers and survival models which improved prediction of OS in mRCC patients over commonly used risk models. Implementation of these models has the potential to improve current risk stratification, although prospective validation will still be necessary.
|Keywords||Apolipoprotein A2 (ApoA2), Metastatic renal cell cancer patients, Overall survival, Prognosis, Risk model, Serum amyloid alpha (SAA), angiostatin, apolipoprotein A2, bevacizumab, cediranib, female, genetic association, glycoprotein, human, interferon, interleukin 2, interleukin 6 antibody, kidney carcinoma, lactate dehydrogenase, major clinical study, male, n [2 [(4 hydroxyphenyl)amino] 3 pyridinyl] 4 methoxybenzenesulfonamide , overall survival, prealbumin, prediction, priority journal, protein analysis, protein blood level, proteomics, retrospective study, risk assessment, risk factor, serology, serum amyloid alpha, signal noise ratio, sorafenib, sunitinib, surface enhanced laser desorption ionization time of flight mass spectrometry, turbidimetry, unclassified drug assay|
|Persistent URL||dx.doi.org/10.1093/annonc/mdp559, hdl.handle.net/1765/20782|
|Note||Free full text at PubMed|
Vermaat, J.S., van der Tweel, I., Mehra, N., Sleijfer, S., Haanen, J.B., Roodhart, J.M., … Giles, R.H.. (2010). Two-protein signature of novel serological markers apolipoprotein-A2 and serum amyloid alpha predicts prognosis in patients with metastatic renal cell cancer and improves the currently used prognostic survival models. Annals of Oncology, 21(7), 1472–1481. doi:10.1093/annonc/mdp559